Rumsfeld Shady Heritage in Pandemic: GILEAD s Intrigues with WHO & Wuhan Lab Bio-Weapons Tests with CIA & Pentagon
veteranstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from veteranstoday.com Daily Mail and Mail on Sunday newspapers.
Weizmann Scientists Design Personalized Approach to Improve Immune System Ability to Kill Cancer
weeklyblitz.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from weeklyblitz.net Daily Mail and Mail on Sunday newspapers.
Background Although vaccination against SARS-CoV-2 is recommended prior to introducing anti-CD20 therapies, limited data are available regarding the evolution of post-vaccinal immunity.
Methods This retrospective study compared anti-Spike antibody titres at 6 and 12 months from SARS-CoV-2 vaccination between patients vaccinated before switching to anti-CD20 (‘Switch’) and two control groups: (1) patients vaccinated under disease-modifying therapies (DMTs) other than fingolimod and anti-CD20 (‘Other DMTs’); (2) patients vaccinated on anti-CD20 (‘Anti-CD20’). Anti-Spike-specific T-cell responses were compared between ‘Switch’ and ‘Anti-CD20’ groups.
Results Fifty-three patients were included in the ‘Switch’ group, 54 in the ‘Other DMTs’ group and 141 in the ‘Anti-CD20’ group. At 6 months, in the subset of patients who received a booster dose, the ‘Switch’ group had lower anti-Spike titres compared with the ‘Other DMTs’ group (median 241.0 IQR (88